Compare Merck & Co., Inc. (MRK) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Merck & Co., Inc. trades at $148 (market cap $363.98B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $118.73. The key difference: Merck & Co., Inc. pays a 2.3% dividend while Direxion NASDAQ 100 Equal Weighted Index Shares pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Direxion NASDAQ 100 Equal Weighted Index Shares nearer its low. Which is the better fit depends on your goals.
| MRK | QQQE | |
|---|---|---|
Market Cap | $363.98B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $156.43 | $124.69 |
52-Week Low | $77.60 | $96.06 |
Enterprise Value | $410.75B | — |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
QQQE trades at $119.78, down 0.8% on the day, with a neutral technical signal overall. The ETF provides equal-weighted exposure to the Nasdaq-100, reducing concentration risk compared to market-cap weighted alternatives. Recent news highlights the potential inclusion of SpaceX in the underlying index, which could drive new investor interest. Technical indicators show mixed signals with bullish moving averages but neutral oscillators.
The outlook for QQQE remains tied to Nasdaq-100 performance, with equal weighting offering defensive characteristics during market rotations. Key risks include tech sector volatility and index composition changes. The ETF's structure provides diversification benefits for investors seeking Nasdaq exposure without heavy concentration in mega-cap tech names.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
